The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma
Abstract Purpose This study aimed to assess the response prediction and prognostic values of different peripheral blood cell biomarkers for advanced lung adenocarcinoma (LUAD) patients receiving first‐line therapy. Methods Patients diagnosed with advanced LUAD as well as healthy controls and patient...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14893 |
| _version_ | 1797813837559234560 |
|---|---|
| author | Ran Zuo Fuyi Zhu Cuicui Zhang Jincheng Ma Jinliang Chen Ping Yue Jinfang Cui Yu Wang Peng Chen |
| author_facet | Ran Zuo Fuyi Zhu Cuicui Zhang Jincheng Ma Jinliang Chen Ping Yue Jinfang Cui Yu Wang Peng Chen |
| author_sort | Ran Zuo |
| collection | DOAJ |
| description | Abstract Purpose This study aimed to assess the response prediction and prognostic values of different peripheral blood cell biomarkers for advanced lung adenocarcinoma (LUAD) patients receiving first‐line therapy. Methods Patients diagnosed with advanced LUAD as well as healthy controls and patients with benign pulmonary diseases were collected in this retrospective study. Propensity score matching (PSM) was performed in a 1:1 ratio. Survival state was estimated by the Kaplan–Meier method and the Cox proportional hazard model was used to assess the prognostic factors. Results Compared with the control groups, the level of peripheral blood leucocyte, neutrophil, monocyte, platelet, and neutrophil to lymphocyte ratio, monocyte to lymphocyte ratio, platelet to lymphocyte ratio, and systemic inflammation response index (SIRI) were higher in LUAD patients (all p < 0.001). Some inflammatory markers decreased at the time of optimal response and then increased again as the disease progressed. Multivariate analysis revealed that SIRI and lactate dehydrogenase (LDH) were independent prognostic factors no matter before or after PSM analysis. Area under the curve (AUC) of SIRI and LDH were 0.625 (p < 0.001) and 0.596 (p = 0.008), respectively. When SIRI and LDH were combined, the AUC reached 0.649 (p < 0.001). Conclusions Pretreatment SIRI was an independent prognostic factor of progression free survival (PFS) in advanced LUAD patients. Dynamic monitoring of inflammatory index changes could help to predict therapeutic efficacy. The combination of SIRI and LDH is expected to be a promising clinically accessible biomarker in the future. |
| first_indexed | 2024-03-13T07:58:36Z |
| format | Article |
| id | doaj.art-ee132c2b713140c4a1ef794fa5b3bf4b |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-13T07:58:36Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-ee132c2b713140c4a1ef794fa5b3bf4b2023-06-02T01:27:25ZengWileyThoracic Cancer1759-77061759-77142023-06-0114161500151110.1111/1759-7714.14893The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinomaRan Zuo0Fuyi Zhu1Cuicui Zhang2Jincheng Ma3Jinliang Chen4Ping Yue5Jinfang Cui6Yu Wang7Peng Chen8Department of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Oncology Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaAbstract Purpose This study aimed to assess the response prediction and prognostic values of different peripheral blood cell biomarkers for advanced lung adenocarcinoma (LUAD) patients receiving first‐line therapy. Methods Patients diagnosed with advanced LUAD as well as healthy controls and patients with benign pulmonary diseases were collected in this retrospective study. Propensity score matching (PSM) was performed in a 1:1 ratio. Survival state was estimated by the Kaplan–Meier method and the Cox proportional hazard model was used to assess the prognostic factors. Results Compared with the control groups, the level of peripheral blood leucocyte, neutrophil, monocyte, platelet, and neutrophil to lymphocyte ratio, monocyte to lymphocyte ratio, platelet to lymphocyte ratio, and systemic inflammation response index (SIRI) were higher in LUAD patients (all p < 0.001). Some inflammatory markers decreased at the time of optimal response and then increased again as the disease progressed. Multivariate analysis revealed that SIRI and lactate dehydrogenase (LDH) were independent prognostic factors no matter before or after PSM analysis. Area under the curve (AUC) of SIRI and LDH were 0.625 (p < 0.001) and 0.596 (p = 0.008), respectively. When SIRI and LDH were combined, the AUC reached 0.649 (p < 0.001). Conclusions Pretreatment SIRI was an independent prognostic factor of progression free survival (PFS) in advanced LUAD patients. Dynamic monitoring of inflammatory index changes could help to predict therapeutic efficacy. The combination of SIRI and LDH is expected to be a promising clinically accessible biomarker in the future.https://doi.org/10.1111/1759-7714.14893advanced lung adenocarcinomabiomarkerspredictiveprognosticsystemic inflammation response index |
| spellingShingle | Ran Zuo Fuyi Zhu Cuicui Zhang Jincheng Ma Jinliang Chen Ping Yue Jinfang Cui Yu Wang Peng Chen The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma Thoracic Cancer advanced lung adenocarcinoma biomarkers predictive prognostic systemic inflammation response index |
| title | The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma |
| title_full | The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma |
| title_fullStr | The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma |
| title_full_unstemmed | The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma |
| title_short | The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma |
| title_sort | response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma |
| topic | advanced lung adenocarcinoma biomarkers predictive prognostic systemic inflammation response index |
| url | https://doi.org/10.1111/1759-7714.14893 |
| work_keys_str_mv | AT ranzuo theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT fuyizhu theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT cuicuizhang theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT jinchengma theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT jinliangchen theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT pingyue theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT jinfangcui theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT yuwang theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT pengchen theresponsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT ranzuo responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT fuyizhu responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT cuicuizhang responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT jinchengma responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT jinliangchen responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT pingyue responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT jinfangcui responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT yuwang responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma AT pengchen responsepredictionandprognosticvaluesofsystemicinflammationresponseindexinpatientswithadvancedlungadenocarcinoma |